The purpose of this correspondence is to discuss the TrialsTracker, presented by Powell-Smith and Goldacre in their article 'TrialsTracker: Automated ongoing monitoring of failure to share clinical trial results by all major companies and research institutions ' (2016) as a tool to discover publication bias in clinical trial results. The findings from one specific organization (European Organization for Research and Treatment of Cancer; EORTC) are compared with the actual publication history of the trials in question. We also present shortcomings of the method being used and suggestions for improvement to the proposed algorithm.
We read with great interest the article by Drs Powell-Smith and Goldacre 1 on the incomplete reporting of clinical trial results by pharmaceutical companies and research institutions. The necessity to publish results of all clinical trials, regardless of the trial outcome, cannot be denied 2 . Failure to do so is unethical not only towards patients who have participated in these trials but also towards the medical community at large which relies on unbiased reporting to make informed decisions both in clinical practice and research 3 .
The European Organization for Research and Treatment of Cancer (EORTC), as a non-profit pan European clinical research organization, very much supports this view. EORTC is driven by the mission to improve the survival and quality of life of cancer patients, and adheres to a strict policy to publish all of its completed trials in full 4 . We were therefore surprised by the results from TrialsTracker 5 stating that 52.6% of EORTC trials are missing results (20 trials out of 38). We downloaded the full trial dataset used by the tracker via GitHub (https://github.com/ebmdatalab/trialstracker). After selection according to the set criteria (ie. completed since 01/01/2006, interventional phase II or III, led by EORTC) a total of 29 relevant trials were found. The tracker classified these as: 14 with successful result reporting and 15 (51.7%) without results. We identified the latter 15 trials through the NCT ID number and cross-referenced this with the EORTC internal bibliography list. This (manual) investigation yielded the following results (see Table 1 ): -A total of 9 trials had been successfully published, but the NCT ID number was not listed in PubMed's Secondary Source ID field. For all of these trials the NCT ID was stated in the article itself and a link to the correct reference was provided in the publications section of ClinicalTrials.gov -Three further trials had been recently successfully published without mention of the NCT ID number. The reference was not yet present in ClinicalTrials.gov but was scheduled to be updated soon.
-The last three trials were still undergoing analysis, and the planned publications were in various stages of development.
This would put the EORTC under-reporting "score" at 3/29 or about 10% of its trials being overdue for publication.
Our investigation revealed several shortcomings of the automated tracker algorithm:
-The decision to only accept results posted directly in ClinicalTrials.gov or with a listed NCT ID in PubMed's Secondary Source ID field is very restrictive. EORTC does not post results in ClinicalTrials.gov directly as this presents a substantial administrative burden, and does not allow results to be put into context. Other organizations may be in the same situation.
-The authors state that since 2005 "all major medical journals (through the International Committee of Medical Journal Editors) have required trials to be registered, and all trials should include their registry ID in the text." The majority of our trials, as identified by the tracker, fulfill these criteria, yet several were incorrectly classified due to absence of a specific PubMed field provided by the medical journals. Despite this omission, these trial results could be correctly found through recognized databases such as ClinicalTrials.gov and PubMed or even a standard search engine like Google.
-For at least two studies, the NCT ID PubMed link was available for a publication that did not contain the actual study results. The EORTC 55971 study on neoadjuvant treatment in ovarian cancer was published in NEJM in 2010 6 . Yet this publication was not identified by the tracker, but two subsequent publications on exploratory subgroup analyses were considered as evidence of trial results publication 7, 8 .
We also want to introduce two caveats to take into account when refining a tracker such as the one proposed:
-The algorithm can be easily manipulated to inflate the success rate for any trial sponsor by either not listing trials as completed or by listing them as terminated in the registry.
-Also, once the trial is completed, any publication with an adequate NCT ID PubMed link is sufficient for the TrialsTracker algorithm, which means articles on quality assurance, subgroups, translational research, prognostic models, or other data not containing actual trial results will inflate the statistics.
As a general observation, we feel that tracking publications linked to trials without checking these publications for accuracy and adequacy represents a simplistic measure of publication reporting. A substantial source of bias lies in the incorrect publication of trial results, often done with the intention to present larger treatment effects 9 . We feel such a tracking system, by increasing pressure to publish all trials on short notice, may contribute to the problem by leading to compromises on the quality of the publication.
A straightforward approach to resolve this could be to add to clinical trial registries an indicator on the publication status of final trial results. The sponsor would be responsible for updating this indicator and for providing the actual reference. Registry administrators could then check the appropriateness of the reference based on criteria already required to check online posting of results, therefore providing independent confirmation that the trial results are adequately published. Such an indicator would allow for more accurate reporting and could be used to set up an automatic alert system.
The EORTC welcomes initiatives to improve clinical trial reporting. The EORTC has an explicit data sharing policy (http://www. eortc.org/investigators/data-sharing/) that allows anyone to request direct access to clinical trial data from completed studies. In Our conclusion is that the proposed TrialsTracker is a much needed and welcome initiative. However, in this first implementation it is too simplistic to be of real informative use and its conclusions are misleading. We hope that improvements to the algorithm will converge in a useful tool that can address the very real and serious concern of unreported clinical trial results.
Author contributions CC prepared the first draft. JB and LC were involved in the revision of the draft manuscript and have agreed to the final content.
Competing interests
All authors are employees of the EORTC.
Grant information
The author(s) declared that no grants were involved in supporting this work. This article is necessarily limited in scope as it presents results for just one trial sponsor, and we do not know if that sponsor is representative. However, as the authors are from just one institution, it is of course perfectly reasonable that they have focused on their own institution, so this is not intended as a criticism, merely as an observation.
NCT ID number EORTC ID number
Coens have done a good job of presenting a more detailed analysis of the studies from their et al institution, and have shown convincingly that the estimate of their publication rate from the automated Trial Tracker was substantially inaccurate for their institution, by means of the gold standard of a manual search. They provide a sensible and balanced discussion of the limitations of the automated search algorithm more generally, pointing to some possible unintended consequences. While those unintended consequences are at this stage purely speculative, it does no harm to bear in mind what the risks are of an automated process such as the Trials Tracker.
I have 2 suggestions for improving the paper. First, Coen state that only 29 of the 38 trials identified et al by the Trials tracker were "eligible studies", which they define as "completed since 01/01/2006, interventional phase II or III, led by EORTC". When I applied those criteria myself to the EORTC trials identified by the Trials Tracker, I found 30 eligible studies. As far as I could tell from the Trials Tracker data, all 38 studies were completed since 01/01/2016 and were led by EORTC, and 8 studies were not drug interventions. It would be helpful if Coen could be more explicit about why they excluded 9 trials et al from their analysis.
Second, I think the finding that some trials were not identified as published by the Trials Tracker despite a publication that was clearly linked in the clinicaltrials.gov record deserves more emphasis. Although this is mentioned in the paper, a casual reader might miss it, and this is perhaps the most important finding in terms of a way in which the Trial Tracker could easily be improved. I don't see how 38 changed to 29 (number of relevant EORTC studies). The said criteriacompleted, has completion_date and it is later than 1 Jan 2006, interventional, phase 2 or 3 -results indeed in 38 records. Yet, Coens reports only 29, saying that these are "relevant", but et al how they define relevance (ie. what 9 studies were excluded and why) is not discussed at all. Table 1 should be improved by clearly marking which trial belongs to which category: has results or not, in the latter case the reason from the three listed (NCT ID not in SI field, no NCT ID given in the publication, really not published). In the current form it is difficult to match the concrete trials to the authors' statements (e.g. what are the trials that have a publication but not NCT ID given?).
My major comments are therefore rather about missing details and potential further improvements:
TrialsTracker looks up results from clinicaltrials.gov (results section) and Pubmed (only through NCT ID as SI). While non-publication in Pubmed might have several -not necessarily malicious or negligent -reasons, such as the publication being rejected or a long review process, clinicaltrials.gov has no such limitation, so non-disclosure there seems to be much more inexcusable at first glance. Coens touches this issue, but only extremely briefly, stating that et al "[uploading results to clinicaltrials.gov] presents a substantial administrative burden, and does not allow results to be put into context''. I'd really welcome a more detailed discussion of the first part: how large is this burden, is it in fact prohibitive...? (Especially for organizations with tens of thousands of employees and clinical trials with a budget in excess to ten million US dollars.) As far as the second part is concerned, I disagree: the aim of the deposition of results in repositories is 
